TRANXENE TRANXENE TRANXENE

Dose: 7.5 to 15 mg
Single Dose: 11 (11.25)
Frequency: 12 hourly
Route: PO
Instructions: Frequency may be increased upto 4 times/day if needed.

Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group

Dose: 7.5 mg
Single Dose: 7.5 (7.5)
Frequency: 24 hourly
Route: initial dose mentanance
Instructions:

. It is of Synthetic origin and belongs to Benzodiazepine. It belongs to Psychotherapeutic Drugs and Antianxiety Agent pharmacological group.The Molecular Weight of Clorazepate (K) is 408.90. Its pKa is 12.23.

Clorazepate (K) is contraindicated in conditions like Pulmonary insufficiency,Narrow-angle glaucoma,Hypersensitivity.

The severe or irreversible adverse effects of Clorazepate (K), which give rise to further complications include Aggression, Jaundice, Dependence, Psychological impairment, Cerebral atrophy.Clorazepate (K) produces potentially life-threatening effects which include Blood dyscrasias. which are responsible for the discontinuation of Clorazepate (K) therapy.The signs and symptoms that are produced after the acute overdosage of Clorazepate (K) include Coma, Drowsiness, Respiratory depression, Ataxia, Nystagmus, Mental confusion.The symptomatic adverse reactions produced by Clorazepate (K) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Vertigo, Headache, Drowsiness, Irritability, Ataxia, Skin rashes, Dry mouth, Blurred vision, Confusion, GI upset, Tremor, Diplopia, Nightmares, Paradoxical rage, Slurred speech, Syncope, Euphoria, Xerostomia.

Clorazepate (K) is primarily indicated in conditions like Alcohol withdrawal, Anxiety, Insomnia, Neurosis, Partial seizures, Premedication in anaesthesia, Psychoneurosis, Psychosomatic disorders, Suppression of transplant rejection, and can also be given in adjunctive therapy as an alternative drug of choice in Epilepsy.

Clorazepate (K) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAlcoholAmprenavirIncreased risk of prolonged sedation and respiratory depression when Amprenavir given with Clorazepate.MajorAntazolineIncreased antimuscarinic and sedative effects when antihistamines (e.g Antazoline) given with anxiolytics (e.g Clorazepate).Cimetidine (HCl)ClozapineFluconazoleIndinavir (Sulphate)ItraconazoleKetoconazoleMephenytoinMetoprolol (Tartrate)Both agents acts additively thus increases hypotensive and/or CNS depressant effects.ModerateClosely monitor for hypotension and excessive or prolonged CNS depression.Propranolol (HCl)Both agents acts additively thus enhances hypotensive and/or CNS depressant effect.ModerateClosely monitor for hypotension and excessive or prolonged CNS depression.RitonavirTelithromycinVORICONAZOLEVoriconazole may increase the serum concentration of clorazepate by decreasing its metabolismMonitor for clonazepam toxicity if voriconazole is initiated or dose increased. These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Drug should not be given to Paediatrics, Pregnant Mothers, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Tab Store in a well closed container, Below 40°C. Protect from Sunlight and Moisture.

Perform periodic blood counts and liver function tests during long term therapy. Clorazepate potassium should be used with caution in patients if increased salivation cause respiratory difficulty, because it may produce an increase in salivation. Give least amount of drug to patients in whom depression accompanies anxiety and suicidal tendencies may be present. It should be used with caution (if it contain tartrazine) in patients with aspirin hypersensitivity because it may cause allergic reaction (including bronchial asthma).